Beta Bionics vs Pfizer
Side-by-side comparison of AI visibility scores, market position, and capabilities
Beta Bionics (Nasdaq: BBNX) makes the iLet Bionic Pancreas, the first autonomous closed-loop insulin delivery system; reported Q1 2026 revenue of $27.6M (+57% YoY) with 24,000+ active users.
About
Beta Bionics is a commercial-stage medical device company focused on transforming the management of insulin-requiring diabetes. Its flagship product is the iLet Bionic Pancreas, a device that automates insulin delivery using a proprietary adaptive algorithm that requires no carbohydrate counting, correction boluses, or manual basal rate programming from the user — the system learns from glucose readings and autonomously adjusts insulin delivery to maintain target glucose levels. The iLet is compatible with continuous glucose monitors including Dexcom G6, Dexcom G7, and FreeStyle Libre 3 Plus.
Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.
About
Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.